Find care
Short answer
TeleWellnessMD and GobyMeds offer online visits with licensed clinicians who can prescribe peptide and related medicines where your state allows.
Online visits with licensed U.S. clinicians. Prescriptions are filled by U.S. compounding pharmacies.
Opens telewellnessmd.com.
Online clinic for prescription programs.
Opens gobymeds.com.
Start with a clinic that serves your state. A licensed clinician should review your health before deciding, so no clinic should promise a prescription. Some popular peptides are not on the U.S. Food and Drug Administration (FDA) list of ingredients pharmacies may use, so a legit clinic may say no.
Look up the clinician's license on your state's website: the medical board for doctors, the nursing board for nurse practitioners. It must cover the state you are in during the visit (Florida also accepts a telehealth registration). Check the pharmacy that fills it with your state board of pharmacy. FDA says to avoid sites that do not require a prescription.
They are sections of federal law. A 503A pharmacy is state-licensed and compounds for one patient from a prescription. A 503B outsourcing facility registers with FDA. Compounded medicines from either are not FDA-approved.
Checked September 26, 2026.
FDA keeps a list of ingredients compounding pharmacies may use while it reviews them (Category 1). On FDA's list updated May 14, 2026, BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, MOTS-c, epitalon, DSIP, selank, semax, and thymosin alpha-1 are not on it: their nominations were withdrawn, so they are not in any category. Source
On July 23 and 24, 2026, FDA's Pharmacy Compounding Advisory Committee met to discuss adding BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax and Epitalon to the list of ingredients pharmacies may use. FDA's meeting page, last updated August 6, 2026, does not post a result. The National Community Pharmacists Association reported on July 31, 2026 that the committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, and voted against emideltide (DSIP). It also reported that the votes are advice, not binding on FDA, that the Secretary of Health and Human Services must still approve any addition, and that pharmacies may not compound these peptides until a final rule is in place. Source · News report
FDA lists kisspeptin-10 in Category 2, substances that raise significant safety risks in compounding. Source
GHK-Cu is in Category 1 for uses other than injection. FDA says it intends to ask its Pharmacy Compounding Advisory Committee about GHK-Cu before the end of February 2027. Source
Ask any clinic which of these it prescribes, whether each is FDA-approved or compounded, and where the pharmacy is. Read the full guide: are peptides legal?